✦ LIBER ✦

A phase II, randomized, open-label, pilot study to evaluate the safety and the effects on bone resorption of saracatinib (AZD0530) in patients with prostate cancer or breast cancer with metastatic bone disease

✍ Scribed by M. Aklilu*; A. Hussain; C.P. Evans; R.A. Hannon; A. Lipton; M. Dimairo; J. Yu; P. Zobel; F.M. Torti; R.D. Finkelman

Book ID: 116323969
Publisher: Elsevier Science
Year: 2011
Tongue: English
Weight: 56 KB
Volume: 48
Category: Article
ISSN: 8756-3282
DOI: 10.1016/j.bone.2010.10.044

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase II open-label randomized study t

A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy

✍ György Bodoky, Constanta Timcheva, David Robert Spigel, Phillip Joseph La Stella 📂 Article 📅 2011 🏛 Springer US 🌐 English ⚖ 640 KB

Erratum to: A phase II open-label random

Erratum to: A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy

✍ György Bodoky, Constanta Timcheva, David Robert Spigel, Phillip Joseph La Stella 📂 Article 📅 2011 🏛 Springer US 🌐 English ⚖ 61 KB

AOSOP6 Results from the 2-year open-labe

AOSOP6 Results from the 2-year open-label extension treatment phase of a pivotal phase 3 study of denosumab in patients with breast cancer and bone metastases previously treated with zoledronic acid or denosumab

✍ A.T. Stopeck; A. Lipton; M. Martín; J-J. Body; A. Paterson; G.G. Steger; K. Tonk 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 42 KB

Phase II, Open-Label, Randomized, Multic

Phase II, Open-Label, Randomized, Multicenter Study Comparing the Efficacy and Safety of Olaparib, a Poly (ADP-Ribose) Polymerase Inhibitor, and Pegylated Liposomal Doxorubicin in Patients With BRCA1 or BRCA2 Mutations and Recurrent Ovarian Cancer

✍ Kaye, S. B.; Lubinski, J.; Matulonis, U.; Ang, J. E.; Gourley, C.; Karlan, B. Y. 📂 Article 📅 2012 🏛 American Society of Clinical Oncology 🌐 English ⚖ 165 KB

Final safety and efficacy analysis of th

Final safety and efficacy analysis of the specific endothelin A receptor antagonist zibotentan (ZD4054) in patients with metastatic castration-resistant prostate cancer and bone metastases who were pain-free or mildly symptomatic for pain: a double-blind, placebo-controlled, randomized Phase II trial

✍ Nicholas D. James; Armelle Caty; Heather Payne; Michael Borre; Bernard A. Zonnen 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 428 KB

Corrigendum to: “Re: The Efficacy and Sa

Corrigendum to: “Re: The Efficacy and Safety of Degarelix: A 12-Month, Comparative, Randomized, Open-Label, Parallel-Group Phase III Study in Patients with Prostate Cancer” by Dieter Jocham and Christian Doehn [Eur Urol 2009;55:1488–9]

✍ Bo-Eric Persson 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 47 KB